Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis-Reference-Cited by-同舟云学术

Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis

Published:2019-06-07 Issue:2 Volume:1 Page:
ISSN:2631-827X
Container-title:Crohn's & Colitis 360
language:en
Short-container-title:

Author:

Boden Elisa K¹²^ORCID,Canavan James B³⁴⁵,Moran Christopher J⁶⁷,McCann Katelyn⁴,Dunn William A⁴⁵,Farraye Francis A⁸,Ananthakrishnan Ashwin N⁵⁷,Yajnik Vijay⁵⁷,Gandhi Roopali⁵⁹,Nguyen Deanna D⁵⁷,Bhan Atul K¹⁰¹¹,Weiner Howard L⁵⁹,Korzenik Joshua R³⁵,Snapper Scott B³⁴⁵

Affiliation:

1. Division of Gastroenterology, Virginia Mason Medical Center, Seattle, WA

2. Benaroya Research Institute, Seattle, WA

3. Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Boston, MA

4. Division of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, Boston, MA

5. Department of Medicine, Harvard Medical School, Boston, MA

6. Division of Pediatric Gastroenterology, MassGeneral Hospital for Children, Boston, MA

7. Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA

8. Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, MA

9. Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Boston, MA

10. Department of Pathology, Massachusetts General Hospital, Boston, MA

11. Department of Pathology, Harvard Medical School, Boston, MA

Abstract

Abstract Aim The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC). Methods An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The primary end points were changes in immunologic parameters and evaluation for safety. Results Six subjects received oral OKT3. Biologic effects of oral anti-CD3 included significantly increased proliferation in response to anti-CD3 and anti-inflammatory gene expression profile in peripheral blood mononuclear cells. No serious treatment-related adverse events occurred. Conclusion Orally delivered anti-CD3 resulted in immunologic changes in patients with UC.

Funder

Mason Diamond Fund

National Institutes of Health

National Institute of Diabetes Digestive and Kidney Disease

Wolpow Family Chair in IBD Treatment and Research

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology

Link

http://academic.oup.com/crohnscolitis360/advance-article-pdf/doi/10.1093/crocol/otz009/28786606/otz009.pdf

Reference29 articles.